Amgen and AstraZeneca’s Tezspire (tezepelumab) has achieved a significant milestone with positive results from the Phase III CROSSING trial, demonstrating its efficacy in treating symptomatic and uncontrolled eosinophilic esophagitis (EoE). This success potentially marks a third major indication for the blockbuster therapy, building upon its established approvals in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The findings, which highlight improvements in both swallowing difficulties and underlying inflammation, are expected to pave the way for regulatory submissions and further solidify Tezspire’s position in the landscape of epithelial-driven inflammatory diseases.
Main Facts:
- Positive Phase III Results: The CROSSING trial (NCT05583227) met its two co-primary endpoints, demonstrating Tezspire’s effectiveness in adult and adolescent patients with eosinophilic esophagitis (EoE).
- Improved Swallowing Function: Patients treated with Tezspire experienced a statistically significant improvement in ease of swallowing compared to placebo at week 24, with this benefit sustained through week 52.
- Histologic Remission Achieved: Tezspire also significantly increased the proportion of patients achieving histologic remission, defined as eosinophil counts of six or fewer per high-power field (HPF) in esophageal biopsies. This threshold is considered stringent within the field.
- Favorable Safety Profile: The safety and tolerability of Tezspire in the EoE population were consistent with its established profile in previously approved indications.
- Potential for New Label Expansion: If approved for EoE, Tezspire will expand its therapeutic reach beyond severe asthma and CRSwNP, reinforcing its role in managing epithelial inflammatory conditions.
- Strong Market Outlook: Analysts project peak sales exceeding $4 billion for Tezspire following potential approval in EoE, underscoring its significant commercial potential.
Chronology of Tezspire’s Development and Approvals:
Tezspire, a novel biologic developed through a collaboration between Amgen and AstraZeneca, represents a significant advancement in the treatment of inflammatory diseases driven by epithelial dysfunction. Its journey began with a focus on respiratory conditions, leveraging its unique mechanism of action as a thymic stromal lymphopoietin (TSLP) blocker.
The initial breakthrough for Tezspire came with its approval for severe asthma. TSLP is a key cytokine implicated in the inflammatory cascade of allergic diseases, and by blocking its action, Tezspire aims to disrupt the underlying drivers of inflammation. Clinical trials demonstrated its ability to reduce severe exacerbations in patients with moderate-to-severe asthma, irrespective of their eosinophil levels, a notable distinction from some other biologics. This led to its initial regulatory greenlight from the U.S. Food and Drug Administration (FDA).
Following its success in asthma, the therapeutic potential of Tezspire was explored in other epithelial-driven inflammatory conditions. Chronic rhinosinusitis with nasal polyps (CRSwNP) emerged as another promising area. CRSwNP is characterized by chronic inflammation of the nasal passages and sinuses, often accompanied by the formation of nasal polyps, leading to significant nasal congestion, loss of smell, and reduced quality of life. Clinical studies showed that Tezspire, as an add-on maintenance treatment, could effectively reduce polyp size and improve symptoms in patients with inadequately controlled CRSwNP. This led to its subsequent approval for this indication, further broadening its clinical utility.
The development trajectory of Tezspire has been marked by strategic expansion into areas with significant unmet needs. Eosinophilic esophagitis (EoE) represents such an area. EoE is a chronic, immune-mediated esophageal disease characterized by the infiltration of eosinophils into the esophageal lining, leading to inflammation, dysphagia (difficulty swallowing), food impaction, and abdominal pain. While existing treatments aim to manage symptoms and reduce inflammation, there remains a need for therapies that offer sustained relief and address the underlying disease processes effectively.
The CROSSING trial, specifically designed to evaluate Tezspire’s efficacy and safety in adult and adolescent patients with symptomatic and uncontrolled EoE, represents a critical step in this expansion. The trial’s design, focusing on key clinical and histological outcomes, was crucial for demonstrating the drug’s multifaceted benefits in this complex condition.
Supporting Data and Clinical Efficacy:
The topline results from the CROSSING trial provide compelling evidence for Tezspire’s therapeutic value in EoE. The trial’s design incorporated two critical co-primary endpoints, ensuring a comprehensive assessment of the drug’s impact:
1. Improvement in Ease of Swallowing:
One of the most debilitating symptoms of EoE is dysphagia, or difficulty swallowing. The CROSSING trial measured the improvement in swallowing function by assessing patient-reported outcomes. The results indicated that patients treated with Tezspire experienced a statistically significant improvement in their ease of swallowing compared to those who received a placebo. This improvement was evident at the 24-week mark, a crucial time point for assessing initial treatment response. Furthermore, the study demonstrated that this beneficial effect on swallowing was not transient but was sustained through to week 52, suggesting a durable impact on a key clinical manifestation of EoE. This sustained improvement is particularly significant for patients who often face chronic challenges with eating and nutrition, impacting their overall well-being and quality of life.
2. Achievement of Histologic Remission:
Beyond symptom relief, addressing the underlying inflammation is paramount in managing chronic diseases like EoE. Histologic remission, characterized by a significant reduction in eosinophil counts in the esophageal tissue, is a key marker of disease control. In the CROSSING trial, Amgen and AstraZeneca defined histologic remission as an eosinophil level of six or fewer per high-power field (HPF) across multiple esophageal biopsies. This specific threshold is noteworthy, as research has shown considerable variability in the criteria used to define histologic remission in EoE. The fact that Tezspire met this stringent endpoint signifies a substantial impact on the esophageal inflammatory infiltrate. Achieving histologic remission is crucial for preventing long-term esophageal remodeling and potential complications associated with chronic inflammation. The success in meeting this endpoint suggests Tezspire not only alleviates symptoms but also actively modulates the core pathological processes of EoE.
Safety and Tolerability:
A critical aspect of any new drug indication is its safety profile. The CROSSING trial reported that the safety and tolerability of Tezspire in the EoE patient population were consistent with its established profile in severe asthma and CRSwNP. This reassuring data suggests that patients with EoE can expect a similar risk-benefit ratio to those treated for its current indications, further bolstering confidence in its potential for widespread adoption.
Mechanism of Action and Differentiated Approach:
Tezspire’s mechanism of action as a TSLP blocker differentiates it from other biologics. TSLP is an epithelial-derived cytokine that plays a crucial role in initiating and amplifying inflammatory responses in various allergic and atopic diseases. By targeting TSLP at its source, Tezspire intervenes early in the inflammatory cascade, potentially impacting a broader range of inflammatory pathways compared to agents that target downstream cytokines like IL-4, IL-5, or IL-13. This upstream blockade may contribute to its broad efficacy across different eosinophilic and non-eosinophilic inflammatory profiles observed in severe asthma, and its potential utility in conditions like EoE where TSLP is implicated.
Official Responses and Expert Opinions:
The positive outcomes of the CROSSING trial have been met with enthusiasm from both the developing companies and external observers.
Amgen’s Perspective:
Jay Bradner, Executive Vice President of R&D, AI, and Data at Amgen, articulated the significance of the trial results. He stated, "In this Phase III trial, Tezspire improved both the underlying inflammation and the swallowing difficulties that can make EoE so disruptive for patients. That combination is important for patients and builds confidence in Tezspire as a potential new treatment for people struggling with EoE." This statement highlights the dual benefit of Tezspire – addressing both the symptomatic burden and the pathological underpinnings of EoE. The emphasis on the "combination" underscores the value of a therapy that offers comprehensive relief, a key desideratum for patients managing chronic and debilitating conditions.
AstraZeneca’s Outlook:
While a direct quote from AstraZeneca is not provided in the original text, their consistent involvement in the development and commercialization of Tezspire indicates a strong belief in its expanded potential. The company’s revenue reports and analyst projections, as mentioned in the article, reflect an optimistic outlook for Tezspire’s future market performance, with the potential EoE indication being a significant contributor.
Medical Community’s Anticipation:
The positive Phase III data is anticipated to be presented at an upcoming medical conference, where it will undergo peer review and detailed discussion within the scientific and clinical communities. Experts in gastroenterology and allergy are likely to scrutinize the data, particularly concerning the stringent definition of histologic remission and the long-term sustainability of the observed benefits. The potential for a new, effective therapeutic option for EoE, a condition with historically limited treatment choices, is a cause for considerable optimism.
Implications and Future Outlook:
The potential approval of Tezspire for eosinophilic esophagitis carries significant implications for patients, healthcare providers, and the pharmaceutical industry:
For Patients:
The prospect of a new, effective treatment for EoE offers a beacon of hope for individuals suffering from this chronic and often life-altering condition. The demonstrated improvement in swallowing difficulties and the achievement of histologic remission suggest that Tezspire could lead to a substantial enhancement in quality of life, allowing patients to eat more comfortably, reduce the risk of food impaction, and potentially mitigate long-term esophageal damage. The consistency of its safety profile with existing indications is also a crucial factor for patient acceptance and adherence.
For Healthcare Providers:
The addition of Tezspire to the therapeutic armamentarium for EoE will provide physicians with a valuable new tool for managing this complex disease. The drug’s mechanism of action and its demonstrated efficacy in addressing both symptoms and underlying inflammation offer a differentiated approach. The availability of detailed data from the CROSSING trial will enable clinicians to make informed treatment decisions and tailor therapy to individual patient needs.
For the Pharmaceutical Landscape:
The potential approval of Tezspire in EoE reinforces its status as a "blockbuster" therapy and expands its market reach significantly. Amgen and AstraZeneca’s strategic expansion of Tezspire’s indications across various epithelial-driven inflammatory diseases highlights a successful development strategy. GlobalData analysts’ forecast of peak sales exceeding $4 billion underscores the immense commercial potential, positioning Tezspire as a key revenue driver for both companies.
Competitive Environment:
While Tezspire’s entry into the EoE market is promising, it will face competition. Notably, Dupixent (dupilumab), developed by Sanofi and Regeneron, is already an established therapy for EoE, demonstrating efficacy in reducing esophageal eosinophil counts and improving symptoms. Takeda’s Eohilia (budesonide oral suspension) is another approved option. The comparative effectiveness, long-term outcomes, and cost-effectiveness of Tezspire against these existing treatments will be critical factors in its market penetration. However, Tezspire’s unique mechanism of action and its success in other inflammatory conditions suggest it may offer a valuable alternative or adjunctive therapy for a significant patient population.
Next Steps:
Following the positive topline results, Amgen and AstraZeneca are set to share the detailed findings with regulatory authorities. This will initiate the formal review process, with the expectation of seeking approval for Tezspire as a treatment for EoE. The companies have also committed to presenting the comprehensive study data at an upcoming medical conference, allowing for in-depth scientific discussion and analysis.
In conclusion, the successful completion of the CROSSING trial marks a pivotal moment for Tezspire and for patients suffering from eosinophilic esophagitis. The drug’s ability to significantly improve swallowing function and achieve histologic remission, coupled with a favorable safety profile, positions it as a highly anticipated new therapeutic option. This potential expansion of its label not only bolsters Tezspire’s legacy but also signifies a critical advancement in the management of epithelial-driven inflammatory diseases, underscoring the ongoing commitment to innovation in addressing unmet medical needs.
About the Author
